Bone grafting is one of the commonest surgical procedures, yet all bone
substitutes developed so far suffer from specific weaknesses and the search for
a bone graft material with ideal physical and biological properties is still
ongoing. Calcium phosphate pastes are the most frequently used synthetic bone
grafts, yet they (a) often take an impractically long time to set, (b) release
the drug content too fast, and (c) do not form pores large enough to accommodate
host cells and foster osseointegration. To make up for these deficiencies, we
introduced gelatin and silica to pastes composed of 5–15 nm sized
hydroxyapatite nanoparticles and yielded a bioresorbable composite that is
compact, yet flowing upon injection; that prevents setting at room temperature,
but sets promptly, in minutes, at 37 °C; that displays an increase in
surface porosity following immersion in physiological fluids; that allows for
sustained release of antibiotics; and that sets in a tunable manner and in
clinically relevant time windows: 1–3 minutes at its fastest. Timelapse,
in situ X-ray diffraction analysis demonstrated that the
setting process is accompanied by an increase in crystallinity of the initially
amorphous hydroxyapatite, involving no polymorphic phase transitions in its
course. Setting time can be tuned by controlling the weight content of gelatin
or powder-to-liquid ratio. The release of vancomycin was slow, ~ 8 %
after 2 weeks, and unaffected by the gelatin content. While vancomycin-loaded
pastes were effective in reducing the concentration of all bacterial species
analyzed, the bacteriostatic effects of the antibiotic-free pastes were
pronounced against S. liquefaciens and E. coli. S.
liquefaciens bacilli underwent beading and filamentation during the
treatment, suggesting that the antimicrobial effects are attributable to cell
wall disruption by hydroxyapatite nanoparticles. Vancomycin-loaded pastes
augmented the activity of the antibiotic against P. aeruginosa
and S. liquefaciens, while exhibiting no negative effects
against human mesenchymal stem cells. They were also uptaken three times more
abundantly than pure hydroxyapatite, indicating the theoretical favorability of
their use for intracellular delivery of therapeutics. This selectivity, toxic
for bacteria and harmless for primary stem cells, is promising for application
as bone grafts for osteomyelitis.